ADVANCED THERAPY IN PATIENTS WITH PRIMARY AND POSTPOLYCYTHEMIC MYELOFIBROSIS
Ph-negative myeloproliferative neoplasm are the group of hematologic disorders which includes primary myelofibrosis, polycythemia vera, essential trombocytemia and several rare diseases. After the discovery of V617 Fgain-of-function mutation the new period of diagnostics, treatment and evaluating of...
Guardado en:
Autores principales: | A. N. Alekseeva, O. E. Ochirova, L. B. Sodnomova, E. B. Zhalsanova |
---|---|
Formato: | article |
Lenguaje: | RU |
Publicado: |
Scientific Сentre for Family Health and Human Reproduction Problems
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a4815a4296a44801ba5a931e35d897bd |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Evaluating the Safety, Efficacy, and Therapeutic Potential of Momelotinib in the Treatment of Intermediate/High-Risk Myelofibrosis: Evidence to Date
por: Bassiony S, et al.
Publicado: (2020) -
Disseminated tuberculosis with myelofibrosis presentation: a case report
por: Mahdi Khatuni, et al.
Publicado: (2021) -
New Markers of Disease Progression in Myelofibrosis
por: Rita Campanelli, et al.
Publicado: (2021) -
VEGFA rs3025020 Polymorphism Contributes to CALR-Mutation Susceptibility and Is Associated with Low Risk of Deep Vein Thrombosis in Primary Myelofibrosis
por: Laura Villani, et al.
Publicado: (2021) -
Simultaneous hepatosplenic T-cell lymphoma and myelofibrosis
por: Ali M Gabali, et al.
Publicado: (2014)